ABSTRACT
Objective:To investigate the efficacy of Zhibitai capsules combined with low-dose atorvastatin in the treatment of cervical arteriosclerosis and its effects on high-sensitivity C-reactive protein and regulatory T cells in the peripheral blood. Methods:A total of 104 patients with carotid arteriosclerosis admitted to Fenyang Hospital from January 2021 to April 2022 were retrospectively included in this study. They were divided into a control group ( n = 52) and an observation group ( n = 52) according to different treatment methods. The control group was orally given atorvastatin calcium tablets 20 mg once a day. The observation group was orally given atorvastatin calcium tablets 10 mg once a day, and Zhibitai capsules 0.24 g, one capsule in the morning and one capsule in the evening. After 8 weeks of treatment, changes in total cholesterol, triacylglycerol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and regulatory T cell proportion in the peripheral blood were evaluated. Results:After treatment, high-density lipoprotein cholesterol level and regulatory T cell proportion in the observation group were (1.53 ± 0.29) mmol/L and (5.52 ± 1.38)%, respectively, which were significantly higher than (1.19 ± 0.21) mmol/L and (4.48 ± 0.86)% respectively in the control group ( t = 6.84, 4.61, both P < 0.05). Total cholesterol, triacylglycerol, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein levels in the observation group were (2.88 ± 0.27) mmol/L, (1.21 ± 0.15) mmol/L, (2.01 ± 0.19) mmol/L, (2.58 ± 0.43) mg/L, respectively, which were significantly lower than (3.68 ± 0.41) mmol/L, (1.33 ± 0.19) mmol/L, (2.69 ± 0.31) mmol/L, (3.70 ± 0.25) mg/L, respectively in the control group ( t = 11.75, 3.57, 12.31, 17.23, all P < 0.05). There was no significant difference in carotid plaque size pre-treatment between the two groups, but the plaque size decreased after treatment compared with before treatment. The efficacy of Zhibitai capsules combined with low-dose atorvastatin in the treatment of cervical arteriosclerosis in the observation group was superior to that in the control group ( P < 0.05). Conclusion:Oral administration of Zhibitai capsules combined with low-dose atorvastatin for the treatment of cervical arteriosclerosis is safe and has few adverse reactions. The combined therapy can decrease serum high-sensitivity C-reactive protein levels, increase the proportion of regulatory T cells in the peripheral blood, help stabilize plaques, and reduce plaque size.
ABSTRACT
Objective:To investigate the effects of olanzapine versus risperidone on cognitive function, serum complement C3 and C4 levels and high sensitivity C-reactive protein (hs-CRP) level in patients with schizophrenia. Methods:Eighty patients with schizophrenia who received treatment in Lishui Second People's Hospital, China between September 2018 and September 2019 were included in this study. They were randomly assigned to receive treatment either with olanzapine (olanzapine group, n = 40) or risperidone (risperidone group, n = 40). Before and after treatment, the Positive and Negative Syndrome Scale (PANSS) score and the Wisconsin Card Sorting Test score were evaluated in each group. Before and after treatment, serum levels of dopamine, serotonin, norepinephrine, complement C3 and C4 and hs-CRP levels were compared between the olanzapine and risperidone groups. Results:Before treatment, there were no significant differences in PANSS and WCST scores between the two groups (both P > 0.05). After treatment, PANSS score, the number of perseverative errors and the number of random errors in each group were significantly decreased compared with before treatment [olanzapine group: (56.23 ± 9.37) points, (13.06 ± 6.26) points, (16.23 ± 6.35) points, t = 12.334, 5.885, 3.840, all P < 0.05; risperidone group: (55.98 ± 10.21) points, (13.97 ± 6.54) points, (16.31 ± 6.32) points, t = 12.044, 6.213, 3.321, all P < 0.05]. After treatment, the number of correct sorts and the number of categories in each group were significantly increased compared with before treatment [olanzapine group: (29.21 ± 2.24) points, (3.79 ± 1.12) points, t = 3.323, 2.087, both P < 0.05; risperidone group: (29.33 ± 2.35) points, (3.81 ± 1.15) points, t =2.750, 2.085, both P < 0.05]. After treatment, there were significant differences in these indexes between the two groups (all P > 0.05). Before treatment, there were no significant differences in serum levels of dopamine, serotonin and norepinephrine between the two groups (all P > 0.05). After treatment, serum levels of dopamine, serotonin and norepinephrine in each group were significantly decreased compared with before treatment [olanzapine group: (5.02 ± 0.13) μg/L, (66.24 ± 6.05) μg/L, (27.32 ± 4.05) μg/L, t = 67.800, 9.977, 5.082, all P < 0.05; risperidone group: (4.18 ± 0.12) μg/L, (63.12 ± 6.21) μg/L, (24.81 ± 4.13) μg/L, t = 99.761, 12.296, 6.882, all P < 0.05]. After treatment, there were significant differences in serum levels of dopamine, serotonin and norepinephrine between the two groups ( t = 30.029, 2.276, 6.882, all P < 0.05). Before treatment, there were no significant differences in complement C3 and C4 and hs-CRP levels between the two groups (all P > 0.05). After treatment, complement C3 and C4 and hs-CRP levels in each group were significantly increased compared with before treatment [olanzapine group: (1.12 ± 0.18) g/L, (0.24 ± 0.06) g/L, (1.09 ± 0.11) mg/L, t = 5.129, 4.049, 32.452, all P < 0.05; risperidone group: (1.13 ± 0.17) g/L, (0.25 ± 0.07) g/L, (1.10 ± 0.12) mg/L, t = 5.147, 5.164, 29.227, all P < 0.05]. After treatment, there were no significant differences in complement C3 and C4 and hs-CRP levels between the two groups ( t = 0.255, 0.686, 0.389, all P > 0.05). Conclusion:Olanzapine and risperidone have the same effects on improving the mental symptoms and cognitive function of patients with schizophrenia, but risperidone has more obvious effects on improving the body function than olanzapine.
ABSTRACT
Resumen El déficit de lipasa ácida lisosomal es una enfermedad genética poco prevalente, con alta morbimortalidad en niños y adultos. Se caracteriza por alteración del metabolismo lipídico que genera depósitos de ésteres de colesterol y triglicéridos en el organismo. La presentación clínica depende de la actividad enzimática. Se debe sospechar en pacientes con alteraciones lipídicas o alteraciones hepáticas después de descartar otros diagnósticos. Actualmente existe la opción de utilizar enzima recombinante, la cual puede mejorar los parámetros lipídicos y hepáticos, así como detener la progresión de la enfermedad. Es imperioso realizar el diagnóstico oportuno para iniciar de forma temprana el tratamiento específico, con el fin de prevenir la morbimortalidad. Se llevó a cabo revisión de la literatura en torno del déficit de lipasa ácida lisosomal, para orientar acerca de su fisiopatología, manifestaciones clínicas, diagnóstico y tratamiento.
Abstract Lysosomal acid lipase deficiency is a genetic disease with a low prevalence and high morbidity and mortality in children and adults. It is characterized by an alteration of lipid metabolism, which generates cholesterol and triglyceride esters deposits in the body. Its clinical presentation depends on enzymatic activity. This condition should be suspected in patients with lipid or liver alterations after ruling out other diagnoses. Currently, there is the option of using a recombinant enzyme, which can improve lipid and liver parameters, as well as disease progression. Establishing a timely diagnosis in order to initiate specific treatment early is imperative for the prevention of morbidity and mortality. The purpose of this work is to perform a review of the literature about lysosomal acid lipase deficiency and to guide about its pathophysiology, clinical manifestations, diagnosis and treatment.
Subject(s)
Humans , Child , Adult , Wolman Disease/epidemiology , Lipid Metabolism , Wolman Disease/diagnosis , Wolman Disease/physiopathology , Prevalence , Disease ProgressionABSTRACT
Objective@#To analyze the risk factors affecting the poor prognosis of progressive cerebral infarction.@*Methods@#The clinical data of 326 patients with cerebral infarction admitted to Dermatology and Venereal Disease Prevention and Cure Hospital of Zaozhuang from January 2013 to March 2017 were retrospectively analyzed.The patients were divided into poor prognosis group(n=148) and good prognosis group(n=178) according to their prognosis during hospitalization.Univariate analysis and multivariate logistic regression analysis were used to explore the risk factors affecting prognosis.@*Results@#Statistical analysis showed that there were no statistically significant differences in sex composition, average age, diastolic blood pressure, LDL, anterior cerebral artery stenosis, posterior cerebral artery stenosis and vertebral basilar artery stenosis between the two groups (all P>0.05). The incidence rates of hypertension history (60.81% vs. 48.88%, χ2=1.683, P=0.031), diabetes history (41.89% vs. 30.90%, χ2=4.244, P=0.039), hyperlipidemia history (62.84% vs. 49.44%, χ2=5.875, P=0.015) in the poor prognosis group were higher than those in the good prognosis group.The systolic blood pressure in poor prognosis group was lower than that in the good prognosis group [(144±17)mmHg vs. (150±22)mmHg, t=2.928, P=0.004]. The body temperature[(38.10±0.22)℃ vs. (38.03±0.34)℃, t=2.240, P=0.026], FPG[(7.85±1.95)mmol/L vs. (6.91±1.77)mmol/L, t=4.558, P=0.000], TC[(5.21±1.66)mmol/L vs. (4.84±1.55)mmol/L, t=2.708, P=0.039], TG[(2.49±0.79 mmol/L vs. (2.30±0.54)mmol/L, t=2.483, P=0.014], HDL [(1.30±0.51)mmol/L vs. (1.17±0.44)mmol/L, t=2.470, P=0.014] and FIB[(4.37±1.67)g/L vs. (3.79±1.42)g/L, t=3.339, P=0.001], stenosis of internal carotid artery (31.08% vs. 20.79%, χ2=4.636, P=0.031), stenosis of middle cerebral artery(39.86% vs. 29.21%, χ2=4.083, P=0.043), and plaque of internal carotid artery (48.65% vs. 36.52%, χ2=4.882, P=0.027) in the poor prognosis group were higher than those in the good prognosis group.Multivariate regression analysis showed that history of hypertension, diabetes, hyperlipidemia, fever, decreased blood pressure, elevated TC, elevated TG, elevated HDL and elevated FIB were the risk factors for the prognosis of progressive cerebral infarction.@*Conclusion@#There are many risk factors affecting the poor prognosis of progressive cerebral infarction, and the physiological mechanism is complex.In clinical treatment, attention should be paid to patients' past diseases, prevention and treatment should be carried out according to different mechanisms.
ABSTRACT
Objective To analyze the risk factors affecting the poor prognosis of progressive cerebral infarction.Methods The clinical data of 326 patients with cerebral infarction admitted to Dermatology and Venereal Disease Prevention and Cure Hospital of Zaozhuang from January 2013 to March 2017 were retrospectively analyzed.The patients were divided into poor prognosis group(n =148) and good prognosis group(n =178) according to their prognosis during hospitalization.Univariate analysis and multivariate logistic regression analysis were used to explore the risk factors affecting prognosis.Results Statistical analysis showed that there were no statistically significant differences in sex composition,average age,diastolic blood pressure,LDL,anterior cerebral artery stenosis,posterior cerebral artery stenosis and vertebral basilar artery stenosis between the two groups (all P ＞ 0.05).The incidence rates of hypertension history (60.81％ vs.48.88％,x2 =1.683,P =0.031),diabetes history (41.89％ vs.30.90％,x2 =4.244,P =0.039),hyperlipidemia history (62.84％ vs.49.44％,x2 =5.875,P =0.015) in the poor prognosis group were higher than those in the good prognosis group.The systolic blood pressure in poor prognosis group was lower than that in the good prognosis group [(144 ± 17) mmHg vs.(150 ± 22) mmHg,t =2.928,P =0.004].The body temperature [(38.10 ± 0.22) ℃ vs.(38.03 ± 0.34) ℃,t =2.240,P =0.026],FPG [(7.85 ± 1.95) mmol/L vs.(6.91 ± 1.77) mmol/L,t =4.558,P =0.000],TC [(5.21 ± 1.66) mmol/L vs.(4.84 ± 1.55) mmol/L,t =2.708,P =0.039],TG [(2.49 ± 0.79 mmol/L vs.(2.30 ± 0.54) mmol/L,t =2.483,P =0.014],HDL [(1.30 ± 0.51) mmol/L vs.(1.17 ±0.44)mmol/L,t=2.470,P=0.014] and FIB[(4.37± 1.67)g/L vs.(3.79 ± 1.42)g/L,t =3.339,P=0.001],stenosis of internal carotid artery (31.08％ vs.20.79％,x2 =4.636,P =0.031),stenosis of middle cerebral artery (39.86％ vs.29.21％,x2 =4.083,P =0.043),and plaque of internal carotid artery (48.65％ vs.36.52％,x2 =4.882,P =0.027) in the poor prognosis group were higher than those in the good prognosis group.Multivariate regression analysis showed that history of hypertension,diabetes,hyperlipidemia,fever,decreased blood pressure,elevated TC,elevated TG,elevated HDL and elevated FIB were the risk factors for the prognosis of progressive cerebral infarction.Conclusion There are many risk factors affecting the poor prognosis of progressive cerebral infarction,and the physiological mechanism is complex.In clinical treatment,attention should be paid to patients'past diseases,prevention and treatment should be carried out according to different mechanisms.
ABSTRACT
Disminuir el colesterol total y el LDL colesterol mediante el consumo de frutos secos (maní, nuez y almendras) con propiedades antioxidantes para reducir el riesgo de enfermedades cardiovasculares. Método: El presente trabajo es cuantitativo transversal, cuasi-experimental. Se tomó una muestra de 45 participantes del Instituto Interamericano de Cooperación para la Agricultura (IICA), ambos sexos, entre 18 y 65 años de edad, con hipercolesterolemia total mayor a 200 mg/dl y LDL-colesterol mayor a 100 mg/dl uno a ambos alterados. Sin plan nutricional establecido, sin antecedentes de alcohol, tabaco, alergias a frutos secos, hipotiroidismo, mantenimiento actividad física usual y no consumo de estatinas. Los frutos secos fueron maní, nueces y almendras, distribuidos en tres grupos, cada participante consumió 40 gramos diarios de un tipo de fruto seco por seis semanas. Se realizó un pre y post test de examen bioquímico de lípidos intravenoso. Instrumentos utilizados: cuestionario para recolección de datos y pesa de alimentos. Estudio realizado con una confianza estadística estimada (95 por ciento). Resultado: Todos los participantes presentan niveles altos de ambos tipos de colesterol, uno u otro. En promedio estadístico el colesterol total disminuyó 12,7 mg/dl y el LDL colesterol disminuyó 10.88 mg/dl. El colesterol total promedio estadístico disminuye 11,7 mg/dl consumiendo maní, 7,7 mg/dl, consumiendo almendras y 19.4 mg/dl consumiendo nueces. Discusión: El consumo de los frutos secos está asociado con la disminución del colesterol total y LDL colesterol, por sus propiedades antioxidantes, que tiene un afecto protector contra enfermedades cardiovasculares...
Subject(s)
Humans , Male , Adolescent , Adult , Female , Middle Aged , Antioxidants , Arachis , Cardiovascular Diseases , Cholesterol , FruitABSTRACT
Objective To develop an HPLC method for the measurement of n-3 fatty acid index of serum cholesteryl esters.Methods Serum triglycerides were hydrolyzed with ethanolic sodium hydroxide and cholesteryl esters (CEs) were extracted with hexane.The extracted CEs were analyzed by reversed phase HPLC with a UV detection at 205 nm.Cholesteryl eicosapentaenoate and docosahexaenoate ( major n-3 fatty acid cholesteryl esters) were identified by liquid chromatography-tandem mass spectrometry and cholesterol in each CE fraction was measured.Peak areas of CEs were corrected for cholesterol and CE n-3 index was calculated using the corrected peak area and expressed as the percentage of n-3 fatty acid CEs in total CEs.Results The HPLC analysis can be finished in 6 minutes.Triglycerides which interfere with the determination of n-3 fatty acid index, were hydrolyzed with ethanolic sodium hydroxide (4 mol/L) in 30 seconds.The within-run and total CVs for CE n-3 index averaged 0.66% and 0.90%, respectively.CE n-3 indexes of 70 volunteers and 36 coronary heart disease patients apparently healthy subjects and patients with coronary heart disease in Beijing Hospital appeared to be positively skewed and leptokurtic distribution ( skewness = 1.25, kurtosis = 1.70 ).The median of n-3 indices were 0.98% ( 0.37% - 2.40% ).The logarithm of n-3 index appeared to be normal distribution and the average is 0.003 7% with standard deviations of 0.15.The distribution of n-3 indices of gender groups was similar with the total.The medians of females and males were 1.08% (0.60% -2.40%) and 0.95% (0.37% -2.11%) respectively, and the former were significantly higher than the latter( t = - 3.021, P = 0.003 ).Conclusion A new method for the measurement of n-3 index of serum cholesteryl esters by HPLC has been established.It is simple and precise and can be used in predicting cardiovascular diseases risks and monitoring dietary intake of n-3 fatty acids.
ABSTRACT
Vibrio vulnificus cytolysin (VVC) has been implicated as one of the important virulence determinants of V. vulnificus that causes serious septicemia and wound infection. An attempt was made to investigate that VVC could act as a ligand which stimulates intracellular signaling systems. Cholesterol dose-dependently blocked VVC hemolytic activity through oli-gomerization of cytolysin. Among cholesterol derivatives including 7-dehydrocholesterol, cholesteryl esters, deoxycholate, and cholestane tested, only 7-dehydrocholesterol induced oligomerization as well as inactivation of VVC. These results show that oligomerization of VVC is completely dependent on three-dimensional structure of cholesterol where specific interaction of cholesterol at oligomerization sites of VVC is very selective. These findings support the idea that cholesterol which constitute many of cellular plasma membrane could be a receptor of VVC on plasma membrane of target cells.
Subject(s)
Animals , Mice , Bacterial Toxins/antagonists & inhibitors , Cholesterol/chemistry , Cytotoxins/antagonists & inhibitors , Dehydrocholesterols/chemistry , Dose-Response Relationship, Drug , Erythrocytes/drug effects , Hemolysis/drug effects , Molecular Structure , Signal Transduction , Substrate Specificity , Vibrio/chemistryABSTRACT
Objective To investigate the effect of the gene polymorphism of cholesterol ester transfer protein (CETP) on the serum lipid levels in renal transplant patients.Methods Serum total cholesterol (TC),triglyceride (TG),low density lipoprotein (LDL),high density lipoprotein cholesterol (HDLC),apolipoproteins (Apo A1,B,E) and lipoprotein(a) [Lp(a)] were measured. Polymerase chain reaction-restriction fragment length polymophism (PCR-RFLP) was used to detect CETP gene polymorphism in renal transplant recipients.Results Serum levels of TC,TG,HDLC,LDLC,ApoB,ApoE in the renal transplant recipients were increased significantly after transplantation. The allele frequency and the distribution of the TaqⅠ(intron 1) and MSPⅠ(intron 8) genotypes showed no significant difference between the controls and the renal transplant recipients. The serum TG level was significantly higher in renal transplant recipients with the genotype TaqⅠB1/B1 than those in the patients with genotype TaqⅠ B1/B2 and B2/B2. But there was no statistical difference among the serum lipid levels in renal transplant recipients with different MSPⅠgenotypes.Conclusion The serum lipid levels were increased significantly in transplant after transplantation,and the patients with CETP genotype TaqⅠB1/B1 liable to develop hypertrglyceridemia.
ABSTRACT
OBJECTIVE:To establish an HPLC method for the determination of levels of intracellular cholesterol and cholesterol esters in foam cells derived from RAW264.7 murine macrophages so as to obtain a precise measure of foam cells and provide a technical platform for the study of the intracellular cholesterol content change.METHODS:HPLC method was applied to determine the content of cholesterol esters in the foam cells treated with OX-LDL and different concentration of pravastatin.RESULTS:OX-LDL could significantly enhance cellular intake of lipids(P